Opinion|Videos|January 27, 2025
Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options
Panelists discuss the role of ven-ibr in patient populations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is role of ven-ibr in these patient populations?
- When may you opt for this approach over other time-limited therapy options (ven-obi) or continuous BTKi therapy?
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
4
FDA Flashback: Breast Cancer Decisions and News From June 2026
5